复星医药(02196.HK)与重药控股签订有关原材料/产品及服务的互供框架协议
格隆汇6月9日丨复星医药(02196.HK)发布公告,2021年6月9日,公司与重药控股股份有限公司签订《有关原材料/产品及服务的互供框架协议》。同日,公司与复星国际有限公司签订《房屋租赁及物业服务框架协议》(包括涉及房屋承租、出租业务的协议各1份,以下合称“《租赁框架协议》”)及《产品和服务互供框架协议》。
公司表示,该等框架协议系公司与关联方以自愿、平等、互利、公允为原则,以市场价格为基础签订;签订该等框架协议有利于提升集团运营效率,不存在损害公司及非关联股东利益的情形,不影响公司的独立性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.